You are here

Current status and prospects for development of an HSV vaccine.

TitleCurrent status and prospects for development of an HSV vaccine.
Publication TypeJournal Article
Year of Publication2013
AuthorsJohnston, C, Koelle, DM, Wald, A
JournalVaccine
Date Published2013 Sep 6
ISSN1873-2518
Abstract

Herpes simplex virus type 2 (HSV-2) infects 530million people, is the leading cause of genital ulcer disease, and increases the risk of HIV-1 acquisition. Although several candidate vaccines have been promising in animal models, prophylactic and therapeutic vaccines have not been effective in clinical trials thus far. Null results from the most recent prophylactic glycoprotein D2 subunit vaccine trial suggest that we must reevaluate our approach to HSV-2 vaccine development. We discuss HSV-2 pathogenesis, immunity, and vaccine efforts to date, as well as the current pipeline of candidate vaccines and design of trials to evaluate new vaccine constructs.

DOI10.1016/j.vaccine.2013.08.066
Alternate JournalVaccine
PubMed ID24016811